Abstract
High-grade serous ovarian carcinoma (HGSOC) is the most frequent histological type of ovarian cancer and the one with worst prognosis. Unfortunately, the majority of established ovarian cancer cell lines which are used in the research have unclear histological origin and probably do not represent HGSOC. Thus, new and reliable models of HGSOC are needed. Ascitic fluid from a patient with recurrent HGSOC was used to establish a stable cancer cell line. Cells were characterized by cytogenetic karyotyping and short tandem repeat (STR) profiling. New generation sequencing was applied to test for hot-spot mutations in 50 cancer-associated genes and fluorescence in situ hybridization (FISH) analysis was used to check for TP53 status. Cells were analyzed for expression of several marker genes/proteins by reverse-transcription polymerase chain reaction (RT-PCR), fluorescence-activated cell sorting (FACS), and immunocytochemistry (ICC). Functional tests were performed to compare OVPA8 cells with five commercially available and frequently used ovarian cancer cell lines: SKOV3, A2780, OVCAR3, ES2, and OAW42. Our newly-established OVPA8 cell line shows morphologic and genetic features consistent with HGSOC, such as epithelial morphology, multiple chromosomal aberrations, TP53 mutation, BRCA1 mutation, and loss of one copy of BRCA2. The OVPA8 line has a stable STR profile. Cells are positive for EpCAM, CK19, and CD44; they have relatively low plating efficiency/ability to form spheroids, a low migration rate, and intermediate invasiveness in matrigel, as compared to other ovarian cancer lines. OVPA8 is sensitive to paclitaxel and resistant to cisplatin. We also tested two FGFR inhibitors; OVPA8 cells were resistant to AZD4547 (AstraZeneca, London, UK), but sensitive to the new inhibitor CPL304-110-01 (Celon Pharma, Łomianki/Kiełpin, Poland). We have established and characterized a novel cell line, OVPA8, which can be a valuable preclinical model for studies on high-grade serous ovarian cancer.
Highlights
Preclinical studies in cancer research rely mainly on the established cancer cell lines
Later, based on the gene expression profile [2], karyotype analysis, comparative genome hybridization (CGH), and single nucleotide polymorphism (SNP) analysis [3] this line was found to be identical to the M14 melanoma cell line
In our previous study, using expression microarrays we identified a multigene signature related with worse prognosis in High-grade serous ovarian carcinoma (HGSOC)
Summary
Preclinical studies in cancer research rely mainly on the established cancer cell lines. The MDA-N cell line, believed to originate from breast cancer, appeared to be identical with MDA-MB-435. Apart from the problems related with a mix-up of different cell cultures and their cross-contamination, another problematic issue is concerned with their poor original description. Those cell lines that were established many years ago often lack precise information about the patient history, tumor histology, etc. The OVCAR3 cell line has been used as the HGSOC control, and OAW42 is most probably derived from serous ovarian cancer, while the three others, very popular, have unclear histological origin, which is still a matter of debate
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
